What is Nyxoah?
Nyxoah, headquartered in Mont-Saint-Guibert, Belgium, is a pioneering medical technology company dedicated to developing and commercializing novel solutions for Obstructive Sleep Apnea (OSA). The company's innovative approach aims to provide effective and patient-friendly alternatives to existing treatments, addressing a significant unmet need in the global healthcare market. Nyxoah's strategic financing rounds indicate a strong investor confidence in its technology and its potential to disrupt the sleep disorder treatment landscape.
How much funding has Nyxoah raised?
Nyxoah has raised a total of $371.7M across 8 funding rounds:
Series A
$11M
Private Equity
$20M
Private Equity
$27.2M
Stock Offering
$99.6M
Share Placement
$15M
Share Placement
$27M
Stock/Share Issuance
$77M
Private Equity
$95M
Series A (2014): $11M, investors not publicly disclosed
Private Equity (2016): $20M led by Glide Healthcare and Novallia
Private Equity (2020): $27.2M supported by Resmed Inc
Stock Issuance/Offering (2020): $99.6M, investors not publicly disclosed
Share Placement (2023): $15M, investors not publicly disclosed
Share Placement (2024): $27M, investors not publicly disclosed
Stock/Share Issuance (2025): $77M led by Cochlear and ResMed
Private Equity (2026): $95M, investors not publicly disclosed
Key Investors in Nyxoah
Cochlear
Cochlear, a prominent medical device company, is known for its advanced implantable solutions for hearing loss. Their participation suggests a strategic interest in complementary medical technologies and patient care pathways.
ResMed
ResMed is a global leader in developing innovative solutions for sleep-disordered breathing and respiratory conditions. Their investment in Nyxoah highlights a shared focus on improving sleep health and a potential for synergistic advancements in the field.
Glide Healthcare
Gilde Healthcare is a specialized investment firm focused on the healthcare sector, managing substantial assets across venture, growth, and private equity strategies. Their backing of Nyxoah indicates a belief in the company's disruptive potential and its ability to deliver significant value in the medical technology market.
What's next for Nyxoah?
With the recent major strategic investment and substantial overall capital raised, Nyxoah is poised for significant expansion. The company is likely to focus on scaling its commercial operations, further investing in research and development to enhance its product pipeline, and potentially exploring new geographic markets. This enterprise-level funding provides Nyxoah with the resources to solidify its position as a leader in the OSA treatment sector and pursue its mission of improving the lives of millions suffering from sleep apnea.
See full Nyxoah company page
